The market leads globally, supported by strong research infrastructure, favorable regulations, and a high concentration of clinical trials. It is growing due to increasing adoption of advanced therapies, continuous innovation in gene editing technologies, and rising demand for targeted treatments in oncology and rare diseases.
The U.S. cell and gene therapy refers to advanced medical treatments that modify a patient’s cell or genetic cells or genetic materials to correct the underlying cause of disease and restore normal function. The U.S. cell and gene therapy market is expanding rapidly due to strong investment in biotechnology, a robust clinical trials ecosystem, and supportive regulatory pathways that accelerate ecosystems. The rising prevalence of cancer and rare genetic disorders is increasing demand for targeted, potentially curative treatments. Advances in gene and cell engineering technologies, along with growing partnerships between pharma and biotech firms, are driving further innovation, scalability, and commercialization across the country.
The U.S. cell and gene therapy market size was estimated at USD 4.09 billion in 2025 and is predicted to increase from USD 4.74 billion in 2026 to approximately USD 20 billion by 2035, expanding at a CAGR of 17.2% from 2026 to 2035.
Future opportunities in the U.S. cell and gene therapy market fields include expanding into large patient populations through in-vivo approaches, improving manufacturing efficiency, and reducing treatment costs. Continued progress in gene editing, delivery technologies, and automation is expected to enhance accessibility and enable broader adoption across multiple disease areas.
| Parameter | 2023 | 2024 | 2025 |
| FDA-approved therapies | 16 | 19 | 22 |
| Active clinical trials | 3,950 | 4,230 | 4,516 |
| Clinical trial participants | 780,000 | 850,000 | 920,000 |
| Therapies in clinical development | 310 | 335 | 362 |
| Total pipeline (Preclinical + Clinical) | 1,800 | 1,920 | 2,050 |
| Average development programs initiated | 120 | 135 | 150 |
The data reflects steady expansion in the U.S. cell and gene therapy ecosystem from 2023 to 2025, with consistent growth in clinical trials, patient participation, and development programs. The increasing number of approved therapies and pipeline assets highlights accelerating innovation, while rising trial activity indicates stronger research engagement and progress towards broader clinical adoption.
The cell therapy segment dominated the U.S. cell and gene therapy market with shares of 66.20% in 2025 due to its stronger clinical success, especially in oncology through CAR-T treatments, and relatively faster commercialization compared to gene therapies. Established manufacturing processes, increasing approvals, and wider hospital adoption further supported growth, while its ability to deliver immediate therapeutic effects made it more widely used across multiple indications.
The oncology segment held a dominant share in the U.S. cell and gene therapy market of 39.50% in 2025 due to the high global burden of cancer and strong success of advanced therapies like CAR-T and tumor-infiltrating cell treatments. Significant investment, a robust pipeline, and faster regulatory pathways for life-theratening condition accelerated approvals. Additionally, precision medicine approaches and biomarker-driven therapies improved treatment outcomes, increasing across both hematological and solid tumors.
The viral vectors segment held a dominant share of 72% in the U.S. cell and gene therapy market in 2025 due to its high efficiency in delivering genetic material into target cells and proven success in approved gene therapies. Established platforms like AAV and lentiviral vectors offer strong safety and durability profiles. Additionally, extensive clinical validation, scalable manufacturing advancements, and regulatory familiarity have accelerated their adoption across a wide range of therapeutic applications.
The in-house segment held a dominant share of 46.70% in the U.S. cell and gene therapy market in 2025 due to increasing investments in proprietary R&D infrastructure, the need for stringent quality control over complex manufacturing processes, and the strategic desire of biotech firms to protect intellectual property.
The hospitals and specialty clinics segment led the U.S. cell and gene therapy market with a share of 64.50% in 2025 due to their advanced infrastructure, skilled healthcare professionals, and capability to administer complex cell and gene therapies safely. Increasing patient preference for specialized care settings, along with rising availability of approved treatments in oncology and rare diseases, further strengthened their dominance in delivering these advanced therapies.
Leading companies in the U.S. cell and gene therapy market, including Novartis, Gilead Sciences, Bristol Myers Squibb, Pfizer, Amgen, and bluebird bio, dominate through strong CAR-T, gene therapy, and regenerative medicine portfolios. These firms drive innovation in gene editing and viral vector technologies, while emerging biotech players are expanding rapidly in rare disease and oncology applications, strengthening pipeline growth and commercialization.
By Therapy Type
By Indication/Therapeutic Area
By Vectors Type
By Manufacturing Type
By End Use
